Yi-Mi Wu

Active 1997–2025

Also published as
Yi‐Mi Wu · Yi Mi Wu
48
Papers
27,737
Citations
39
h-index
46
i10-index

Citations

Citations per year for Yi-Mi Wu1997: 2 citations1998: 1 citations1999: 1 citations2000: 1 citations2001: 9 citations2002: 13 citations2003: 12 citations2004: 9 citations2005: 20 citations2006: 13 citations2007: 17 citations2008: 11 citations2009: 17 citations2010: 20 citations2011: 23 citations2012: 75 citations2013: 196 citations2014: 208 citations2015: 325 citations2016: 496 citations2017: 519 citations2018: 574 citations2019: 1,511 citations2020: 1,707 citations2021: 1,677 citations2022: 1,153 citations2023: 776 citations2024: 1,154 citations2025: 456 citations2026: 9 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,082 citing papers, 27.9% of this breakdownChina: 2,512 citing papers, 17.2% of this breakdownUnited Kingdom: 919 citing papers, 6.3% of this breakdownCanada: 645 citing papers, 4.4% of this breakdownItaly: 608 citing papers, 4.2% of this breakdownGermany: 578 citing papers, 3.9% of this breakdownFrance: 446 citing papers, 3% of this breakdownAustralia: 405 citing papers, 2.8% of this breakdownSpain: 402 citing papers, 2.7% of this breakdownJapan: 346 citing papers, 2.4% of this breakdownSwitzerland: 302 citing papers, 2.1% of this breakdownNetherlands: 283 citing papers, 1.9% of this breakdown
0%27.9%Other 21.2%

Fields

  • Biochemistry, Genetics and Molecular Biology53.7%
  • Medicine41.9%
  • Immunology and Microbiology1.9%
  • Computer Science0.5%
  • Agricultural and Biological Sciences0.4%
  • Chemistry0.4%
  • Other1.2%

Topics

  • Prostate Cancer Treatment and Research8.1%
  • Cancer-related molecular mechanisms research7.1%
  • Circular RNAs in diseases4.3%
  • Cancer Genomics and Diagnostics4.1%
  • RNA modifications and cancer4%
  • MicroRNA in disease regulation3.5%
  • Other68.9%

Coauthors

All papers

Open in search
  1. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 3,701

  2. Genomic correlates of clinical outcome in advanced prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bruce Montgomery, Himisha Beltran, Elisabeth I. Heath, Howard I. Scher, Philip W. Kantoff, Mary‐Ellen Taplin, Nikolaus Schultz, Johann S. de Bono, Francesca Demichelis, Peter S. Nelson, Mark A. Rubin, Arul M. Chinnaiyan, Charles L. Sawyers - National Academy of Sciences, Proceedings of the National Academy of Sciences 2019 cited by 1,408

  3. The Landscape of Circular RNA in Cancer

    Authors: , , , , , , , , , , , , - Cell 2019 cited by 2,065

  4. The landscape of long noncoding RNAs in the human transcriptome

    Authors: , , , , , , , , , , , , , , , , , , - Nature Genetics 2015 cited by 2,890

  5. The mutational landscape of lethal castration-resistant prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2012 cited by 2,607

  6. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bernardette Ebbs, Gemma Fowler, Desamparados Roda, Wei Yuan, Yi‐Mi Wu, Xuhong Cao, Rachel Brough, Helen N. Pemberton, Roger A’Hern, Amanda Swain, Lakshmi P. Kunju, Rosalind A. Eeles, Gerhardt Attard, Christopher J. Lord, Alan Ashworth, Mark A. Rubin, Karen E. Knudsen, Felix Y. Feng, Arul M. Chinnaiyan, Emma Hall, Johann S. de Bono - New England Journal of Medicine 2015 cited by 2,187

  7. The long tail of oncogenic drivers in prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wassim Abida, Barry S. Taylor, Howard I. Scher, Peter S. Nelson, Johann S. de Bono, Mark A. Rubin, Charles L. Sawyers, Arul M. Chinnaiyan, Nikolaus Schultz, Eliezer M. Van Allen - Nature Genetics 2018 cited by 884

  8. Integrative clinical genomics of metastatic cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Moshe Talpaz, Marcin Cieslik, Arul M. Chinnaiyan - Nature, Nat. 2017 cited by 938

  9. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Cell 2018 cited by 609

  10. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

    Authors: , , , , , , , , , , , , , , , , , - Nature 2014 cited by 962

  11. Activating ESR1 mutations in hormone-resistant metastatic breast cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Genetics 2013 cited by 1,158

  12. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer

    Authors: , , , , , , , , , , , , , , , , - Nature 2019 cited by 298

  13. The protein tyrosine kinase family of the human genome

    Authors: , , - Oncogene 2000 cited by 1,152

  14. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Andrea Sboner, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 591

  15. Identification of Targetable FGFR Gene Fusions in Diverse Cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2013 cited by 738

  16. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Genetics 2013 cited by 819

  17. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2021 cited by 159

  18. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Valerie P. Castle, Raymond J. Hutchinson, Moshe Talpaz, Dan R. Robinson, Arul M. Chinnaiyan - JAMA 2015 cited by 416

  19. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Saad Z. Usmani, Ravi Vij, Jeffrey L. Wolf, Jeffrey A. Zonder, P. Leif Bergsagel, Daniel Auclair, Hearn Jay Cho, Dan R. Robinson, Arul M. Chinnaiyan - Nature Communications 2022 cited by 91

  20. Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Acta Neuropathologica 2023 cited by 34

  21. Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2024 cited by 31

  22. Targeting the MLL complex in castration-resistant prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2015 cited by 216

  23. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 210

  24. The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing

    Authors: , , , , , , , , , , , , , - Genome Research 2015 cited by 191